390 results match your criteria Atherosclerosis Supplements[Journal]


Achilles tendon ultrasonography - A useful screening tool for cardiovascular risk estimation in patients with severe hypercholesterolemia.

Atheroscler Suppl 2019 Mar 29;36:6-11. Epub 2019 Jan 29.

Children's Hospital, Vilnius University Hospital Santaros Klinikos, Lithuania.

Background And Aims: Achilles tendon lesions have long been associated with genetic defects in lipid metabolism and increased risk of cardiovascular diseases (CVD). With this study we aimed to evaluate the usefulness of Achilles tendon ultrasonography in identifying people at greater risk among subjects with severe hypercholesterolemia (SH) in a high-risk population.

Methods: During the period of 2016-2017 a total of 213 participants were enrolled in this case-control study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.002DOI Listing
March 2019
2 Reads

Investigating the association between familial hypercholesterolemia and perceived depression.

Atheroscler Suppl 2019 Mar 29;36:31-36. Epub 2019 Jan 29.

Department of Internal Medicine and Cardiovascular Center, National Taiwan University Hospital, Taipei, 10002, Taiwan; Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, 10020, Taiwan; Department of Environmental and Occupational Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taiwan. Electronic address:

Background And Aims: Inherited familial hypercholesterolemia (FH) increases cardiovascular risks, but perceived depression in FH is unknown. This study aims to explore the association between the FH and perceived depression.

Methods: This study was a hospital-based design, we started to recruit clinical diagnosis of phenotypic FH since 2014 for the Ten Countries Study in the Asia-Pacific region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.007DOI Listing
March 2019
1 Read

Variable expression and penetrance in Portuguese families with Familial Hypercholesterolemia with mild phenotype.

Authors:
I M Gaspar A Gaspar

Atheroscler Suppl 2019 Mar;36:28-30

Metabolic Unit, Pediatric Department, Santa Maria Hospital, Lisboa, Portugal.

Familial hypercholesterolemia is an Mendelian dominant disorder characterized by defects of the low density lipoprotein receptor (LDLR) that result in a defective removal of LDL from plasma, which promotes deposition of cholesterol in the skin (xanthelasma), tendons (xanthomas), and arteries (atherosclerosis). Diagnosis severe clinical phenotype FH with Dutch Lipid Clinic Network Criteria, encompassing history of premature ASCVD, tendon xanthomas, and a family history of hypercholesterolemia and premature ASCVD in relatives is rare in the Portuguese FH patients. There is a variability of the phenotype in FH individuals with clinical diagnosis or genetic mutation (carriers and patients) probably due to environmental factors in the last century, a Mediterranean diet, or a diet without fat food, trans fat food, no smoking, no sedentary life that can interfere with our metabolism, or are consequences of polygenic, epigenetic, acquired defects, modifiers genes and beta-globin asymptomatic carriers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.006DOI Listing
March 2019
4 Reads

Establishing a familial hypercholesterolaemia register - The first year.

Authors:
Myra Tilney

Atheroscler Suppl 2019 Mar 2;36:24-27. Epub 2019 Feb 2.

Department of Medicine, Faculty of Medicine and Surgery, Mater Dei Hospital, University of Malta, B'kara Bypass, Malta; Dept of Primary Care & Public Health, School of Public Health, 319, Global eHealth Unit, Imperial College London, Reynolds Bldg, St Dunstan's Rd, London, W6 8RP, UK. Electronic address:

Background And Aims: Familial hypercholesterolemia (FH) is an autosomal dominant condition raising the risk of premature cardiovascular disease up to twentyfold.[1] [2] It is under-diagnosed and undertreated, in spite of availability of effective treatment. Registers are recommended to assist in the recognition and improvement of the condition since treatment reduces morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.005DOI Listing
March 2019
1 Read

Percutaneous coronary intervention for a Chinese familial hypercholesterolemia homozygous under the guidance of optical coherence tomography.

Atheroscler Suppl 2019 Mar;36:19-23

Beijing Anzhen Hospital, Capital Medical University - Beijing Institute of Heart, Lung and Blood Vessel Diseases, 100029, China; Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. Electronic address:

Homozygous familial hypercholesterolemia developed into severe cardiovascular consequences early. Untreated HoFH usually cannot survive over 30 years old. Acute coronary syndrome(ACS) caused by plaque rupture is one of the main causes of death in HoFH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.004DOI Listing
March 2019
1 Read
2.293 Impact Factor

Familial hypercholesterolemia in China half a century: A review of published literature.

Atheroscler Suppl 2019 Mar 29;36:12-18. Epub 2019 Jan 29.

Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases Beijing, 100029, China; Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. Electronic address:

Aims: To investigate the status of familial hypercholesterolemia (FH) research and the characteristics of patients with FH in China.

Methods: Published papers in Chinese or English language from PubMed, SinoMed and CNKI databases from 1971 to March 2018 were searched using 'Familial hypercholesterolemia', 'Chinese' and 'Han' as keywords. A systematic review of studies on familial hypercholesterolemia was then conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.003DOI Listing
March 2019
1 Read

The frequency of familial hypercholesterolemia amongst patients in the outpatient clinic of the tertiary specialized cardiology center in Kyrgyzstan.

Atheroscler Suppl 2019 Mar 30;36:1-5. Epub 2019 Jan 30.

Kyrgyz State Medical Academy Named After I.K.Akhunbaev, 720020, 92, Akhunbaeva Str, Bishkek, Kyrgyzstan; National Center of Cardiology and Internal Medicine Named After Academician Mirrakhimov M.M., 720000, 3, Togolok Moldo Str, Bishkek, Kyrgyzstan.

Background: Familial hypercholesterolemia (FH) is frequently underdiagnosed. Prevalence of the FH in Kyrgyzstan is unknown.

Aim: to investigate the prevalence of FH amongst patients in the outpatient settings of the tertiary cardiologic center in Kyrgyzstan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2019.01.001DOI Listing
March 2019
2 Reads

Large artery stiffness according to different assessment methods in adult population of St.Petersburg.

Atheroscler Suppl 2018 Sep 24;35:e1-e5. Epub 2018 Aug 24.

Almazov National Medical Research Centre, Saint Petersburg, Russia.

Objective: The aim of the present study was to assess the prevalence of increased arterial stiffness by different diagnostic methods and its association with cardiovascular risk in Russian population-based cohort.

Design And Methods: In terms of Russian epidemiological study ESSE-RF a random selection of 452 apparently healthy Saint-Petersburg inhabitants aged 25-65 years was performed. Fasting lipids, glucose and blood pressure measurements were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2018.08.001DOI Listing
September 2018

Epidemiology of cardiovascular risk factors in two population-based studies.

Atheroscler Suppl 2018 Sep 25;35:e14-e20. Epub 2018 Aug 25.

Epidemiology and Preventive Pharmacology Centre (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133, Milan, Italy.

We aimed to compare cardiovascular risk factors prevalence in Italy and Russia through cross-sectional database analysis. The study has been based on data from ESSE-RF and from baseline of PLIC study, two population-based epidemiological studies aimed to investigate prevalence of risk factors and evaluating contribution of traditional and new risk factors into morbidity and cardiovascular mortality. A total of 2203 patients with left and right intima-media thickness (IMT) measurements constituted the source population (1205 from PLIC study and 998 from ESSE-RF study). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2018.08.003DOI Listing
September 2018
4 Reads

Notch, BMP and WNT/β-catenin network is impaired in endothelial cells of the patients with thoracic aortic aneurysm.

Atheroscler Suppl 2018 Sep 25;35:e6-e13. Epub 2018 Aug 25.

Almazov Federal Medical Research Centre, Akkuratova, 2, 197341, Saint-Petersburg, Russia; Saint-Petersburg State University, Universitetskaya nab., 7/9, St. Petersburg, 199034, Russia; ITMO University, Institute of Translational Medicine, 49 Kronverksky Pr., St. Petersburg, 197101, Russia. Electronic address:

Cellular and molecular mechanisms of thoracic aortic aneurysm are still not clear and therapeutic approaches are mostly absent. The role of endothelial cells in aortic wall integrity is emerging from recent studies. Although Notch pathway ensures endothelial development and integrity, and NOTCH1 mutations have been associated with thoracic aortic aneurysms, the role of this pathway in aneurysm remains elusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2018.08.002DOI Listing
September 2018
11 Reads
2.293 Impact Factor

Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines - Full report.

Atheroscler Suppl 2018 Jun;31:e1-e12

re. Germano de Sousa Group - Centro de Medicina Laboratorial, Pólo Tecnológico de Lisboa, Portugal.

Even with the improvement in lifestyle interventions, a better control of cardiovascular (CV) risk factors, and improvements in CV outcomes, cardiovascular disease (CVD) still persists as the leading cause of morbidity and mortality in Portugal and Europe. Atherogenic dyslipidaemias, namely hypercholesterolaemia, have a crucial and causal role in the development of atherosclerotic CVD. The clinical approach of a patient with dyslipidaemia involves a watchful diagnosis, sustained in lipid and lipoprotein laboratory procedures, which must be harmonized and standardized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2018.04.001DOI Listing
June 2018
1 Read

Prospective crossover study for a standardized comparison of the dextrane sulfate whole blood and plasma apheresis system in patients with cardiovascular disease and severe dyslipidemia.

Atheroscler Suppl 2017 Nov 1;30:99-107. Epub 2017 Jun 1.

Apheresis Center Rostock (ACR), Nephrocare Rostock GmbH, Nobelstr. 53, 18059 Rostock, Germany. Electronic address:

Background And Aims: The objective of this study was a standardized comparison of the safety and effectiveness of the Kaneka (Kaneka Corporation, Osaka, Japan) whole blood (Liposorber DL-100) and plasma (Liposorber LA-15) lipoprotein apheresis (LA) system to optimize the individual therapy of patients with cardiovascular disease and severe dyslipidemia.

Methods: Six chronic LA patients with a pre-treatment LDL-C < 6 mmol/l in steady state received a total of three treatments with the LA-15 device, followed by three treatments with the DL-100 device or vice versa. To achieve a standardized comparison the treated blood volume for any patient was kept identical for both procedures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.026DOI Listing
November 2017
3 Reads

Impact of double filtration plasmapheresis on adhesion molecules levels in patients with stable coronary heart disease after coronary stenting.

Atheroscler Suppl 2017 Nov 31;30:92-98. Epub 2017 May 31.

Department of Nephrology and Blood Purification, Military Medical Academy, 6, Lebedeva Street, 194044 Saint-Petersburg, Russia.

Objective And Methods: Endothelial dysfunction and inflammatory reaction at the site of damage plays a key role in the formation of neointimal hyperplasia, and in the progression of atherosclerosis. The initiating role in these processes is assigned to adhesion molecules. We studied the dynamics of the level of adhesion molecules soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion molecule-1 (sVCAM-1), soluble form of the molecule platelet adhesion and endothelial type-1 (sPECAM-1), sL-, sP-, sE-selectins during double filtration plasmapheresis (DFPP) with use of plasma fractionators (PF) Cascadeflo EC-50W and EC-40W (Asahi Kasei Medical Co. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.024DOI Listing
November 2017
6 Reads

The efficacy of anti-PCSK9 antibodies: Results from recent trials.

Atheroscler Suppl 2017 Nov 1;30:9-18. Epub 2017 Jun 1.

Center of Endocrinology, Diabetes and Preventive Medicine (ZEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. Electronic address:

The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein (LDL) receptor (LDLR) and directs it to the lysosome for degradation. This results in decreased numbers of LDLR available on the cell surface to bind LDL particles and remove them from the circulation and a subsequent increase in circulating LDL-cholesterol (LDL-C) concentrations. Since the role PCSK9 plays in LDL-C metabolism has been discovered in 2003, there have been major efforts in finding efficient and safe methods to inhibit it. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.030DOI Listing
November 2017
1 Read

Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study.

Atheroscler Suppl 2017 Nov;30:86-91

Department of Internal Medicine and Medical Specialties, University of Rome 'Sapienza', Umberto I Hospital, Rome, Italy.

Background: Hypercholesterolaemia is a major risk factor for cardiovascular disease and requires effective therapy in affected patients. Statins, the mainstay of lipid-lowering therapy, can cause side effects, including myalgia, in some patients. Ezetimibe, is frequently used as an add-on therapy for statins, and is also used as a monotherapy in statin-intolerant patients, however elevations in liver transaminases can occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.021DOI Listing
November 2017
7 Reads

Cascade screening for familial hypercholesterolemia: Practical consequences.

Atheroscler Suppl 2017 Nov 1;30:77-85. Epub 2017 Jun 1.

Department of Internal Medicine, Division Vascular Medicine, Erasmus MC, Rotterdam, The Netherlands. Electronic address:

Familial Hypercholesterolemia (FH) is an autosomal dominant disorder mainly caused by mutations in the LDLR gene, resulting in elevated serum cholesterol levels and elevated risk of premature cardiovascular disease (CVD). Timely treatment with lipid lowering medication can lower the risk of CVD to the same level of the normal population. Currently the incidence of FH is estimated at 1 in 240 persons in the Caucasian population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.019DOI Listing
November 2017
8 Reads

CaRe high - Cascade screening and registry for high cholesterol in Germany.

Atheroscler Suppl 2017 Nov 1;30:72-76. Epub 2017 Jun 1.

D•A•CH-Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen e.V., Hamburg, Germany; Synlab Academy, Synlab Holding Germany GmbH, Mannheim, Germany; Clinical Institut for Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria; Medical Clinic V (Nephrology, Hypertension, Rheumatology, Endocrinology, Diabetology), Mannheim Medical Faculty, University of Heidelberg, Mannheim, Germany.

Introduction: Familial hypercholesterolemia (FH) is an inherited disorder of the LDL metabolism, leading to cardiovascular disease, even at young age. This risk can be significantly lowered by early diagnosis and treatment. About 270,000 patients affected in Germany are not diagnosed correctly and only a small number is treated properly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.015DOI Listing
November 2017
10 Reads

Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolism.

Atheroscler Suppl 2017 Nov 1;30:63-71. Epub 2017 Jun 1.

Department of Internal Medicine III, University Hospital Gießen and Marburg GmbH, Gießen, Germany.

Background: Numerous healthcare studies have shown that more than 90% of all patients with dyslipidaemia are not treated adequately.

Objectives: The "Deutsche Gesellschaft zur Bekämpfung von Fettstoffwechselstörungen und ihren Folgeerkrankungen (DGFF)" [German Society of Lipidology], a non-profit professional membership organization, has already made a series of efforts to improve the care of patients suffering from dyslipidaemia. A recent outcome is the nationwide implementation and certification of Lipidological Competence Centres and Networks (LCCNs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.014DOI Listing
November 2017
10 Reads

Analysis of lipid metabolism and its impact on the risk of ischemic heart disease in patients with definite familial hypercholesterolemia.

Atheroscler Suppl 2017 Nov 1;30:56-62. Epub 2017 Jun 1.

Lipidology and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.

Aim: to analyze the relationship between lipid disturbance, including lipoprotein(a) (Lp(a)) levels, and development of ischemic heart disease (IHD) in patients with familial hypercholesterolemia (FH).

Materials And Methods: 81 patients (middle age was 39.1 ± 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.008DOI Listing
November 2017
3 Reads

Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.

Atheroscler Suppl 2017 Nov 31;30:50-55. Epub 2017 May 31.

Scientific Institute for Nephrology (WiNe), Düsseldorf, Germany.

Background: In recent years the Federal Joint Committee (G-BA), a paramount decision-making body of the German health care system required a reassessment of the approval of chronic lipoprotein apheresis therapy for regular reimbursement. Since 2005 an interdisciplinary German apheresis working group has been established by members of both German Societies of Nephrology. In 2009 the working group completed the indication for lipoprotein apheresis with respect to current cardiovascular guidelines and current scientific knowledge for the registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.006DOI Listing
November 2017
3 Reads

Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

Atheroscler Suppl 2017 Nov 1;30:44-49. Epub 2017 Jun 1.

Department of Medicine II for Nephrology, Hypertension and Vascular Risks, AGAPLESION Markus Hospital, Frankfurt, Germany.

According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.005DOI Listing
November 2017
3 Reads

Lipoprotein(a)-apheresis in the light of new drug developments.

Authors:
Anja Vogt

Atheroscler Suppl 2017 Nov 31;30:38-43. Epub 2017 May 31.

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstrasse 1, 80336 Muenchen, Germany. Electronic address:

Elevated levels of lipoprotein(a) (Lp(a)) contribute to the risk of early and severe cardiovascular disease (CVD). Recently <50 mg/dl was recommended as the desirable level for clinical use and decision making. All established medical therapies to lower cholesterol levels have no impact on lowering Lp(a) except niacin which is all too often poorly tolerated and not obtainable everywhere. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.025DOI Listing
November 2017
2 Reads

Management of patients with statin intolerance.

Atheroscler Suppl 2017 Nov 1;30:33-37. Epub 2017 Jun 1.

Lipidology, Department of Internal Medicine III, University Hospital Dresden Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr 74, 01307 Dresden, Germany.

In recent years statins have become an established option in lipid-lowering pharmacotherapy despite the fact that statin intolerance is fairly common. When muscle pains and/or an elevation of the creatine kinase appear, the dose must be lowered in patients with slight symptoms or stopped altogether if the symptoms are more severe. When the symptoms are alleviated and creatine kinase is normalized, re-exposition can be considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.013DOI Listing
November 2017
3 Reads

ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.

Atheroscler Suppl 2017 Nov 1;30:319-325. Epub 2017 Jun 1.

Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany.

Background And Aims: Cardiovascular disease is the major cause of morbidity and mortality in the world. Diabetes and its complications, such as diabetic nephropathy, dramatically increase cardiovascular risk. Association studies suggest that asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthases, plays a role in the pathogenesis of diabetic nephropathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.031DOI Listing
November 2017
19 Reads

In vivo imaging of murine vasodynamics analyzing different mouse strains by optical coherence tomography.

Atheroscler Suppl 2017 Nov 31;30:311-318. Epub 2017 May 31.

Division of Vascular Endothelium and Microcirculation, Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany. Electronic address:

Background And Aims: We tried to circumvent the limitations of standard organ chamber experiments using in vivo optical coherence tomography (OCT) to analyze the vascular function of small arteries in different mouse strains.

Methods: OCT images were acquired with a two-axis galvanometer scanner head. Time series (3 frames per second, 300 × 512 pixel per frame) of cross-sectional images were analyzed with image processing software measuring the time course of vessel lumen dynamics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.023DOI Listing
November 2017
6 Reads

Impact of omega-3 fatty acids on expression of angiogenic cytokines and angiogenesis by adipose-derived stem cells.

Atheroscler Suppl 2017 Nov;30:303-310

Division of Vascular Endothelium and Microcirculation, Department of Medicine III, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany. Electronic address:

Background And Aims: Human adipose-tissue derived stem cells (ADSC) are interesting novel targets in tissue engineering and regenerative medicine with pronounced angiogenic capacities. Furthermore, omega-3 fatty acids have been described to mediate cardioprotective effects, but their role in angiogenesis and vascular regeneration is not well-understood. Here, we analyzed the impact of different omega-3 fatty acids on angiogenesis by ADSCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.040DOI Listing
November 2017
8 Reads

Lectin-like oxidized low-density lipoprotein receptor-1 promotes endothelial dysfunction in LDL receptor knockout background.

Atheroscler Suppl 2017 Nov;30:294-302

Division of Vascular Endothelium and Microcirculation, Department of Medicine III, University Hospital and Medical Faculty Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany. Electronic address:

Objective: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the major receptor for oxidized LDL in endothelial cells. LOX-1 is highly expressed in atherosclerotic plaques. The impact of LOX-1 on development of endothelial dysfunction in large vessels in absence or presence of atherosclerosis-prone conditions has not been studied to date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.020DOI Listing
November 2017
7 Reads

Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.

Atheroscler Suppl 2017 Nov 31;30:286-293. Epub 2017 May 31.

Department of Gynecology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic.

Introduction: Nanoparticle-based drug delivery systems can overcome the dose-limited toxicity of cytostatics. Pegylated doxorubicin-containing liposomes (PLD) are able to reduce cardiotoxicity. PLD quickly (in 2 days) attains therapeutic concentration in tumorous tissue (kinetic targeting), while its distribution in normal tissue, which is a cause of mucocutaneous toxicity (MCT), is delayed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.022DOI Listing
November 2017
2 Reads

Therapeutic Plasma Exchange in a rare case myasthenic crisis after Botox injection.

Authors:
Azita Chegini

Atheroscler Suppl 2017 Nov 31;30:283-285. Epub 2017 May 31.

Blood Transfusion Research Centre, High Institute for Research and Education in Transfusion Medicine, Hemmat Highway, Tehran, Iran. Electronic address:

Background And Aims: Botulinum toxin (Botox) injections are used as a cosmetic treatment to decrease wrinkles in face and chin. Being a neurotoxic agent it minimizes muscle activity, while side effects are usually rare. This article subsequently presents one case of these rare effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.016DOI Listing
November 2017
14 Reads

How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.

Atheroscler Suppl 2017 Nov 31;30:28-32. Epub 2017 May 31.

Extracorporeal Treatment and Apheresis Center, Department of Internal Medicine, University Hospital and Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Lipoprotein apheresis (LA) has been the last-resort therapeutic option in patients suffering from limited pharmaceutical options to lower highly elevated low density lipoprotein cholesterol (LDL-C) levels. Facing the introduction of the proprotein convertase subtilisin/kexine type 9 (PCSK-9) inhibitors, it has been speculated that they might replace LA to a large extend. Given an efficacy of approx. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.012DOI Listing
November 2017
9 Reads

Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulins.

Atheroscler Suppl 2017 Nov 1;30:278-282. Epub 2017 Jun 1.

Extracorporeal Treatment and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr. 74, 01307 Dresden, Germany.

Introduction: Immunoadsorption (IA) is increasingly used instead of plasma exchange due to lower risk of side effects and a higher selectivity. As a consequence of the reduction of immunoglobulins (Ig), the rate of infectious complications might increase in those patients. We therefore aimed to investigate the infection rate following IA without intravenous IG (IVIG) substitution in our apheresis center, where patients do not receive IVIG on a regular basis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.010DOI Listing
November 2017
6 Reads

Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris.

Atheroscler Suppl 2017 Nov 3;30:271-277. Epub 2017 Jun 3.

Department of Dermatology, University Hospital and Carl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Dresden, Germany. Electronic address:

Background: Pemphigus vulgaris is a chronic autoimmune disease characterized by blisters and erosions forming in the mucous membranes and the skin. Many patients are severely impaired by pain, weight loss and increased risk of infections. The disease is mediated by specific autoantibodies directed against desmogleins that contribute to connect keratinocytes in the epidermis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.044DOI Listing
November 2017
7 Reads

Immunoadsorption for treatment of severe atopic dermatitis.

Atheroscler Suppl 2017 Nov 2;30:264-270. Epub 2017 Jun 2.

Department of Dermatology, University Medical Center Mainz, Germany. Electronic address:

Atopic dermatitis (AD) is a common disease affecting up to 10-20% of the population with the largest disease burden in childhood. Treatment options include basic emollient treatment, topical as well as systemic immunosuppressants. The pathogenesis is complex and among various triggers, genetic predisposition and immunological alterations contribute to development of disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.043DOI Listing
November 2017
13 Reads

Immunoadsorption for autoimmune encephalitis.

Atheroscler Suppl 2017 Nov 2;30:257-263. Epub 2017 Jun 2.

Department of Neurology and Neurological Intensive Care Medicine, Specialist Hospital Hubertusburg, Wermsdorf, Germany.

Autoimmune encephalitis is a severe inflammatory disorder of the brain. The discovery that several non-infectious forms of encephalitis are associated with autoantibodies was a breakthrough in the care of this previously untreatable group of patients. The correlation of antibody type and titer with pattern and severity of symptoms was essential for the initiation of immunotherapies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15675688173008
Publisher Site
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.041DOI Listing
November 2017
7 Reads

Comparing the efficacy of three techniques to reduce isoagglutinin titers in AB0 incompatible kidney transplant recipients.

Atheroscler Suppl 2017 Nov 1;30:253-256. Epub 2017 Jun 1.

University Hospital Carl-Gustav-Carus, Department of Medicine III, Division of Nephrology, Germany. Electronic address:

ABO incompatible (ABOi) organ transplantation requires pre-transplant reduction of the recipient's IgG and IgM isoagglutinin titer against the donor to prevent hyperacute rejection. Over the past four years we primarily used unspecific IgG immunoadsorption (IA) for this purpose and combined this selectively with membrane filtration (IAc) to reduce IgM isoagglutinines. In patients with an initial IgG titer against donor below 1:64, plasma exchange (PE) was initiated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.017DOI Listing
November 2017
4 Reads

Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.

Atheroscler Suppl 2017 Nov 3;30:246-252. Epub 2017 Jun 3.

Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. Electronic address:

Objectives: Lipoprotein(a) (Lp(a)) is an independent cardiovascular (CV) risk factor, predisposing to premature and progressive CV events. Lipoproteinapheresis (LA) is the only efficacious therapy for reducing Lp(a). Data comparing the clinical efficacy of LA with respect to reduction of CV events in subjects with elevated Lp(a) versus LDL-C versus both disorders is scarce. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.047DOI Listing
November 2017

Dysregulation of the CD4 T cells lineage differentiation in dyslipidemic patients and impact of lipoprotein-apheresis treatment: A case study.

Atheroscler Suppl 2017 Nov 3;30:238-245. Epub 2017 Jun 3.

Department of Endocrinology and Diabetes, Division of Diabetes and Nutritional Sciences, King's College London, London SE5 9NU, UK; Faculty of Medicine Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany; Department of Medicine III, Technische Universität Dresden, Dresden, Germany.

Background And Aim: Lipoprotein-apheresis (LA) is a therapeutic approach used against severe forms of dyslipidemia in patients who are non-responders or intolerant to pharmacological treatments. However, little is known about the potential pleiotropic effects of LA, particularly regarding the immune system and its regulation. Thus, in an attempt to analyse the potential effects of dyslipidemia and LA on the regulation of CD4 T cells activation and lineage differentiation, we compared the CD4 T cells cytokines secretion profiles of dyslipidemic patients before and after LA with the profiles observed in healthy donors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.046DOI Listing
November 2017

H.E.L.P apheresis exerts long term effects on the capacity of circulating proangiogenic cells.

Atheroscler Suppl 2017 Nov 2;30:232-237. Epub 2017 Jun 2.

Division of Nephrology, Department of Internal Medicine III, University Hospital and Faculty of Medicine Carl Gustav Carus at the Technische Universität, Dresden, Germany; Extracorporeal Treatment and Apheresis Center, Department of Internal Medicine III, University Hospital and Faculty of Medicine Carl Gustav Carus at the Technische Universität, Dresden, Germany. Electronic address:

Background: Severe forms of mono- and polygenetic hypercholesterolemia as well as elevated Lipoprotein (a) (LP(a)) with progressing cardiovascular (CV) disease are indication for lipoprotein apheresis (LA) in Germany. Many studies investigated pleiotropic effects of LA that might contribute to beneficial effects in advanced atherosclerosis. The present study aimed at investigating the potential role of Proangiogenic Cells (PAC) in patients with new onset or chronic LA using the heparin induced extracorporeal LDL-precipitation (H. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.045DOI Listing
November 2017
3 Reads

Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.

Atheroscler Suppl 2017 Nov;30:225-231

Apherese Centrum Rostock (ACR), Nobelstraße 53, Rostock, Germany. Electronic address:

Background: Lipidapheresis was introduced for intractable hyperlipidemia as a more selective therapy than plasma exchange aiming to enhance efficacy and limit side-effects. Although this therapy is regarded safe, multicenter data from routine application are limited. We investigated direct adsorption of lipoproteins (DALI) and lipofiltration (MONET) regarding the short and the long-term safety aspects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.036DOI Listing
November 2017
10 Reads

Efficacy of lipid reduction with DALI and MONET.

Atheroscler Suppl 2017 Nov 1;30:217-224. Epub 2017 Jun 1.

Clinical and Epidemiological Research, Fresenius Medical Care, Else-Kroener-Strasse 1, Bad Homburg, Germany.

Background: Lipidapheresis techniques are increasingly used to treat drug-resistant hyperlipidemia but few efficacy studies under routine application are available. In this multicenter observational study we investigated direct adsorption of lipoproteins (DALI) and lipoprotein filtration (MONET) for the short and the long-term effects on lipid-lowering effects.

Methods: Data of 122 apheresis patients from 11 centers (DALI: n = 78, MONET: n = 44) were prospectively collected for a period of 2 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.035DOI Listing
November 2017
12 Reads

Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.

Atheroscler Suppl 2017 Nov;30:209-216

Extracorporeal Treatment and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany.

Introduction: Lipoprotein apheresis (LA) represents the only effective therapeutic option for patients with elevated Lipoprotein(a) (Lp(a)) levels. We aimed at analyzing the Lp(a) reduction, rebound rates as well as mean interval values between two weekly apheresis sessions, since this might be important for the prediction of the residual cardiovascular risk and development of individualized approaches for this special therapeutic strategy.

Materials And Methods: 20 patients under weekly and 2 patients under twice weekly apheresis were included. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15675688173007
Publisher Site
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.033DOI Listing
November 2017
2 Reads

Lipoprotein apheresis downregulates IL-1α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia.

Atheroscler Suppl 2017 Nov;30:200-208

Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany.

Background And Aims: Dyslipidaemias are associated with cardiovascular mortality and morbidity, driven by unstable atherosclerotic plaques with inflammatory infiltrates. Levels of messenger RNA (mRNA) for pro-inflammatory cytokines have been positively correlated with atherosclerotic disease progression. Therapeutic lipoprotein apheresis (LA) reduces plasma lipid levels and reduces inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.028DOI Listing
November 2017
5 Reads

Effect of different lipid apheresis methods on plasma polyunsaturated fatty acids.

Atheroscler Suppl 2017 Nov 3;30:193-199. Epub 2017 Jun 3.

Medical Department, Division of Hepatology and Gastroenterology (Including Metabolic Diseases), Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany; Medical Department, Division of Gastroenterology, Oncology, Hematology, Rheumatology and Diabetes, Ruppiner Kliniken, Brandenburg Medical School, Neuruppin, Germany; Experimental and Clinical Research Centre, Charité University Medicine, Campus Buch, Berlin, Germany. Electronic address:

Lipoprotein apheresis has been shown to improve the cardiovascular outcome in patients with atherosclerotic disease and therapy-refractory hypercholesterolemia or elevated lipoprotein (a) (Lp(a)). An elevated intake of omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has also been associated with a reduced cardiovascular risk. However, until now only little is known about the effect of apheresis treatment on the levels of omega-6 and omega-3 polyunsaturated fatty acids (n-6 PUFA and n-3 PUFA) in patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.018DOI Listing
November 2017
3 Reads

The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.

Atheroscler Suppl 2017 Nov 31;30:19-27. Epub 2017 May 31.

Center for Endocrinology, Diabetes and Preventive Medicine (ZEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany. Electronic address:

Increased triglyceride levels (higher than ∼1000 mg/dL) are associated with an increased risk for pancreatitis. Apolipoprotein-CIII (apo-CIII) plays a key role in the metabolism of triglycerides and triglyceride-rich lipoproteins. While loss of function mutations in the gene encoding apo-CIII (APOC3) are associated with low triglyceride levels and a decreased risk for cardiovascular disease (CVD), overexpression of APOC3 is associated with hypertriglyceridemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.003DOI Listing
November 2017

Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.

Atheroscler Suppl 2017 Nov 31;30:187-192. Epub 2017 May 31.

Cardiology Research Center, 3rd Cherepkovskaya Street, 15a, 121552, Moscow, Russia. Electronic address:

Objective: To evaluate the association of lipoprotein(a) [Lp(a)] level with short- and long-term outcomes after coronary artery bypass grafting (CABG) and to assess the effect of a 12 month course of weekly lipoprotein apheresis on vein graft patency and coronary atherosclerosis course in post-CABG patients with hyperlipidemia.

Methods: This study was performed in patients after successful CABG and consisted of three parts: a) a retrospective part with computed tomography assessment of vein graft patency in patients with first-year recurrence of chest pain after CABG (n = 102); b) a prospective trial with evaluation of cardiovascular outcomes during follow up time up to 15 years in relation to baseline Lp(a) levels (n = 356); c) an 12-months interventional controlled study in 50 patients with low-density lipoprotein cholesterol (LDL-C) levels >2.6 mmol/L prior to the operation despite statin treatment that allocated into 2 groups: active (n = 25, weekly apheresis by cascade plasma filtration (CPF) plus atorvastatin), and control (n = 25, atorvastatin alone). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.011DOI Listing
November 2017
20 Reads

Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.

Atheroscler Suppl 2017 Nov 1;30:180-186. Epub 2017 Jun 1.

Apherese Centrum Rostock (ACR), Nephrocare Rostock GmbH, Rostock, Germany.

Background: Dyslipidemia is a well-known risk factor for atherosclerosis and subsequent cardiovascular disease (CVD). While low density lipoprotein cholesterol (LDL-C) is well-established and taken into consideration for risk management and therapy, lipoprotein(a) is another established CVD risk factor frequently not undergoing screening due to a lack of medical treatment options. For patients suffering from CVD due to massive elevation of Lp(a) in presence of normal LDL-C levels, lipoprotein apheresis is the only available treatment option. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.009DOI Listing
November 2017
9 Reads

Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.

Atheroscler Suppl 2017 Nov 1;30:174-179. Epub 2017 Jun 1.

Helios Klinikum Emil von Behring, Klinik für Gefäßmedizin, Walterhöferstraße. 11, 14165 Berlin, Germany. Electronic address:

Objective: Elevated plasma levels of lipoprotein(a) [Lp(a)], referred to as lipoprotein(a)-hyperlipoproteinemia [Lp(a)-HLP], are an independent risk factor for atherosclerosis. Lipoprotein apheresis (LA) enables an effective reduction of Lp(a) plasma levels. The present study investigates the effects of LA in patients with Lp(a)-HLP and peripheral artery disease (PAD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.007DOI Listing
November 2017
11 Reads

Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.

Atheroscler Suppl 2017 Nov 31;30:166-173. Epub 2017 May 31.

Atherosclerosis Department, Institute of Clinical Cardiology named after A.L. Myasnikov, Federal State Institution "Russian Cardiology Research and Production Center" of Ministry of Health of the Russian Federation, 15A, 3d Cherepkovskaya Street, Moscow 121552, Russia.

Background: An elevated lipoprotein(a) (Lp(a)) level is observed in more than 30% of patients with stable ischemic heart disease (SIHD). We conducted an investigation of the effects of specific Lp(a) apheresis on the progression of atherosclerosis in SIHD patients with Lp(a) levels greater than 50 mg/dL.

Methods: We prospectively enrolled 15 patients diagnosed with SIHD based on symptom-driven coronary angiography findings, with Lp(a) ≥50 mg/dL and a low density lipoprotein cholesterol (LDL-C) ≤2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.004DOI Listing
November 2017
4 Reads

Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis.

Atheroscler Suppl 2017 Nov 31;30:159-165. Epub 2017 May 31.

3rd Department of Internal Medicine, Metabolism and Gerontology, University Hospital Hradec Králové and Medical Faculty Charles University in Hradec Králové, Czech Republic.

Oxidative stress is thought to play an important role in the pathogenesis of disorders associated with atherosclerosis. Alpha-tocopherol is considered to be an effective lipophilic antioxidant, which protects lipid membranes against peroxidation and thus prevents cell damage by reaction with free radicals. However, measurement of alpha-tocopherol concentration in serum does not reflect the content of α-tocopherol in membranes whereas erythrocyte alpha-tocopherol may be good indicator of antioxidative status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.002DOI Listing
November 2017